Steven Reichling

Steven Reichling, listed as finance chief, appears in our data through filings on Accelerate Diagnostics, Inc shares, published by SEC (Form 4). The record holds 25 filings, for trades running from 29 September 2015 to 13 March 2023.

On the open market, the record shows 5 purchases worth €41k and 9 sales worth €1.2M. Netting one side against the other leaves €1.2M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 11 option exercises. In 2023 alone, the filings show no purchases and 4 sales.

Half of the purchases are above €8,118 and half below. On 3 out of 4 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The record was last updated on 15 March 2023 with an option exercise in Accelerate Diagnostics, Inc. The last insider purchase was made public on 22 August 2022, 1,540 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.